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Abstract
The transcription factor RUNX2  is the osteogenic mas-
ter gene expressed in mesenchymal stem cells during 
osteogenic commitment as well as in pre-osteoblasts 
and early osteoblasts. However, RUNX2 is also ectopical-
ly expressed in melanoma and other cancers. Malignant 
melanoma (MM) is a highly metastatic skin cancer. The 
incidence of MM has increased considerably in the past 
half-century. The expression levels and mutation rates 
of genes such as BRAF , KIT , NRAS , PTEN, P53 , TERT 
and MITF  are higher in melanoma than in other solid ma-
lignancies. Additionally, transcription factors can affect 
cellular processes and induce cellular transformation 
since they control gene expression. Recently, several st-
udies have identified alterations in RUNX2 expression. 
In particular, the regulation of KIT  by RUNX2 and the 
increased expression of RUNX2 in melanoma specimens 
have been shown. Melanocytes, whose transformation 
results in melanoma, arise from the neural crest and 
therefore show “stemness” features. RUNX2  plays an 
important role in the re-activation of the MAPK and PI-
3K/AKT pathways, thus endowing melanoma cells with 
a high metastatic potential. In melanoma, the most 
frequent metastatic sites are the lung, liver, brain and 
lymph nodes. In addition, bone metastatic melanoma 
has been described. Notably, studies focusing on RUNX2 
may contribute to the identification of an appropriate 
oncotarget in melanoma. 
Key words: RUNX2; Mesenchymal stem cells; Epitelial 
mesenchymal transition; Bone; Melanoma
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: In addition to its physiological expression in 
osteogenic cells, RUNX2  ectopic expression is also re-
ported in several cancers. Melanoma cells, which arise 
from the neural crest, are not typical epithelial cells and 
Maria Teresa Valenti, Luca Dalle Carbonare, Monica Mottes
exhibit “stemness” features. For this reason the epithelial 
mesenchymal transition process may be enhanced in 
melanoma cells. RUNX2  expression in such context in-
creases the migration and invasiveness of melanoma 
cells; it can therefore be considered a new oncotarget in 
melanoma.
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the osteogenic master gene RUNX2 in melanoma. World J Stem 
Cells 2018; 10(7): 78-81  Available from: URL: http://www.
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INTRODUCTION 
In recent times, the incidence of malignant melanoma 
(MM) has increased. The increased number of MM pa­
tients may be ascribed to lifestyle and environmental 
changes. Unfortunately, the mortality rate of MM is 
very high, as MM is highly metastatic and genetically 
resistant to apoptosis. The surgical treatment of skin 
lesions before cell spreading is considered a successful 
therapeutic approach. However, after metastasis and 
dissemination of cells has occurred, the therapeutic 
tools are limited. Despite an initial positive response 
to treatment, melanoma cells become resistant to 
chemotherapy[1]. Many studies performed in animal 
models and in cell culture have identified the complex 
mechanism involved in the metastatic progression of 
melanoma. Mutations in master transcription regulato­
rs such as BRAF, KIT, NRAS, PTEN, P53, TERT, and 
MITF have been found frequently[2]. In particular, the 
microphthalmia­associated transcription factor (MITF) 
is an important oncogene, and it plays a critical role in 
melanoma transformation due to its role in melanocyte 
proliferation and differentiation[3]. However, transcription 
factors in general may affect cellular processes and 
thereby induce cellular transformation. Among them, 
RUNX2, the master gene of osteogenic differentiation, 
has been shown to be involved in the transformation 
and metastatic progression of melanoma[4­6]. RUNX2, 
together with RUNX1 and RUNX3, belongs to the RU­
NT­related gene family[7]. These heterodimeric trans­
cription factors have a DNA­binding “A” subunit and a 
non­DNA binding “B” subunit. The genomic and cDNA 
structures of the RUNT family members are evoluti­
onarily conserved[8]. RUNX2 is located on human chr­
omosome 6; its coding sequence is organized in eight 
exons and controlled by two promoters. Isoforms may 
originate by the alternative use of promoters or by 
the alternative splicing of exons; however, the DNA-
binding domain remains invariant[7]. RUNX2 induces 
the commitment of mesenchymal stem cells to the ost­
eogenic lineage by acting either as a monomer or as 
a heterodimeric complex, which shows a higher DNA 
binding activity[7]. Interestingly, differences in RUNX2 
expression are associated with the skeletal differen-
79WJSC|www.wjgnet.com
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ces between modern humans and Neanderthals[9]. 
Otto et al[10] using an in vivo model, showed that the 
ossification process is lacking in RUNX2 KO mice. 
RUNX2 is expressed not only in mesenchymal stem ce-
lls to commit these cells to osteogenic differentiation 
but also in pre­osteoblasts and early osteoblasts. It 
is then downregulated, as its continuous expression 
would prevent osteoblast maturation. This aspect is im­
portant for bone remodelling. In acromegaly patients, 
who are characterized by an excessive production of 
GH and IGF­1, a high fracture risk occurs; we have 
demonstrated that RUNX2 gene overexpression induc-
es bone loss and impairs bone remodelling in these 
patients[11].
RUNX2 OVEREXPRESSION IN CANCER
The RUNX family members are frequently deregula­
ted in human cancer. Runx proteins are involved in 
critical cellular processes such DNA repair, apoptosis, 
hypoxia, the inflammatory response, EMT, stem cell fu-
nctions, and oncogene­induced senescence, and they 
interact with different signalling pathways such as the 
RAS-ERK, WNT, TGFβ, BMP and Notch pathways[12]. In 
addition, RUNX2 is involved in osteolytic diseases, ne­
oangiogenic processes, and invasion and metastasis of 
solid tumours[4]. RUNX2 can be associated with HDA6 
and can thereby prevent the pro­apoptotic activity of 
P53 through its deacetylation[13]. RUNX2 is ectopically 
expressed in several solid tumours such as breast can-
cer, pancreatic cancer, prostate cancer, lung cancer, and 
ovarian epithelial cancer; therefore, we have proposed 
RUNX2 as a mesenchymal stem marker for cancer[14,15]. 
Interestingly, we observed higher levels of RUNX2 
expression in cancer patients with bone metastases 
compared to patients without bone metastases[15]. In 
thyroid cancer patients, we observed higher expression 
of RUNX2 in cancer tissue as well as in circulating mR­
NA compared to those levels of RUNX2 expression in 
controls[16]. In addition, RUNX2 expression was higher 
in cancer patients with microcalcifications compared 
to patients without microcalcifications[16]. Finally, it has 
been reported that RUNX2 induces its target genes 
SDF­1, CXCR7 and BSP, promoting bone homing[17].
RUNX2 IN MELANOMA
Ectopic expression of RUNX2 in melanoma tissue and 
in melanoma cell lines has been shown to be associated 
with bone sialoprotein (BSP)[18]. BSP has been associa­
ted with tumour invasiveness[18]. RUNX2 also regulates 
several matrix metalloproteinases that are involved in 
melanoma progression; therefore, RUNX2 may be reg­
arded as a common regulator of both BSP and metall­
oproteinases[19]. This finding could also explain the ex-
pression of other bone proteins, such as osteopontin 
and osteocalcin, in melanoma[20,21]. TGFβ, which induces 
metastasis formation in advanced melanoma stages[22], 
can upregulate the expression of RUNX2 in melanoma 
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cell lines[23]. In contrast, the tumour suppressor p14ARF 
reduces RUNX2 expression[24]. Loss­of­function p14ARF 
mutations lead to increased expression of RUNX2 and 
melanoma progression[24]. Ectopic expression of RUNX2 
in melanoma has been associated with invasiveness; 
it has been demonstrated that RUNX2 overexpression 
mediates the migration ability of melanoma cells[6]. Not­
ably RUNX2 stimulates VEGF gene expression[25] and 
the upregulation of angiogenesis, consequent to RUNX2 
overexpression, may represent a critical step for tumor 
metastasis. 
Furthermore, RUNX2 overexpression upregulates 
SOX9, SNAI2 and SMAD3. These transcription factors 
are involved in EMT as well as in cytoskeletal remodelli-
ng and thus enhance the motility and invasive potential 
of cancer cells[17]. In melanoma, the overexpression of 
EGF­R, PDGFRβ, AXL and IGF­1R induces the reactiva­
tion of the MAPK and PI3K/AKT pathways, which are 
involved in migration and invasion processes[26]. The re­
activation of these pathways is due to tyrosine kinase 
receptor­based autocrine loops, in which RUNX2 plays 
a pivotal role[5]. The MAPK and AKT pathways regulate 
most physiological processes, such as proliferation, dif­
ferentiation and cell survival. It has been suggested th­
at the MAPK and AKT pathways are strongly associated 
with each other in melanoma; the link between the 
PI3K/AKT (AKT pathway) and MAPK/ERK1/2 (MAPK 
pathway) cascades is well known[27]. AKT enhances 
RUNX2 expression either directly or by inactivating RU-
NX2 regulators. Similarly, RUNX2 activates the PI3K/
AKT pathway by regulating different components[4]. 
This reciprocal activation induces tumour progression 
and aggressiveness. In addition, RUNX2 promotes the 
crosstalk between MAPK and AKT through EGFR, as 
has been shown in human mammary epithelial cells[28] 
through the reduction of ERK-mediated inhibition of 
EGFR and the AKT pathway. The lung, liver, brain and 
lymph nodes are the most frequent metastatic sites for 
melanoma cells[29]. Since melanocytes arise from the 
neural crest, they are not typical epithelial cells; they sh­
ow “stemness” features. This last finding could partially 
explain the high metastatic potential of melanoma[29]. 
Solid malignancies such as breast, prostate and lung 
cancers form metastases in bone. However, metastatic 
bone diseases from MM are under­investigated. The 
data in the literature report an incidence of skeletal 
metastases in MM patients that ranges from 0.85% to 
18.6%[30]. Recently, Zekri et al[31], managing MM patients 
at two referral cancer centres in England, showed that 
bone metastases occur in 4.1% of patients at all stages 
of MM. In addition, another study showed that 17.2% of 
metastatic melanoma patients had metastases in bone 
tissue. 
CONCLUSION
MM accounts for less than 5% of cutaneous malign­
ancies. However, its incidence has been increasing con­
siderably in the past half-century. Therefore, extensive 
research focusing on the genes involved in melanoma 
transformation and on the modulation of these genes 
is needed. Several studies have highlighted the invo­
lvement of RUNX2, the master gene of osteogenic 
differentiation, in melanoma. The invasiveness and me­
tastatic features conferred by RUNX2 seem to be rela­
ted to its ability to promote EMT. In addition, melanocyt-
es are not typical epithelial cells, and their stemness 
features could explain melanoma invasiveness. Since 
metastatic melanoma has a poor prognosis, new and 
more effective therapeutic tools should be developed in 
order to implement current therapies. In this context, the 
exploitation of molecules actually involved in melanoma, 
such as RUNX2, represents an important frontier for 
the identification of new oncotargets. Transcription facto-
rs have been ignored thus far by the pharmaceutical 
industry; nonetheless, many studies have identified their 
central role in cellular transformation. We believe that 
future efforts directed towards unravelling the complex 
roles of RUNX2 may contribute to the identification of 
new therapeutic tools that improve the quality of life of 
melanoma patients.
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